Quaking and miR-155 interactions in inflammation and leukemogenesis

Area of Science:

• Immunology
• Oncology
• Molecular Biology

Background:

• Quaking (QKI) is a tumor suppressor gene encoding an RNA-binding protein with downregulated expression in solid tumors.
• QKI's role in immune response and leukemogenesis suppression is under investigation.

Purpose of the Study:

• To investigate the role of QKI in the immune response and its regulation by microRNA-155 (miR-155).
• To explore QKI's involvement in the p38 MAPK pathway and its implications in chronic lymphocytic leukemia (CLL).

Main Methods:

• Analyzing QKI expression in lipopolysaccharide (LPS)-challenged macrophages.
• Investigating the effect of QKI overexpression and ablation on inflammatory signaling pathways (JNK, p38 MAPK) and cytokine production (IL-10, IL-1α, IL-1β, IL-6).
• Assessing Fas expression and Caspase3/7 activity.
• Examining QKI expression in CLL-derived MEC2 cells and in B-cell chronic lymphocytic leukemia (B-CLL) patients.

Main Results:

• LPS challenge reduces QKI expression in a miR-155-dependent manner.
• QKI modulates LPS-induced JNK and p38 MAPK phosphorylation and IL-10 production.
• QKI ablation affects Fas expression, Caspase3/7 activity, and pro-inflammatory cytokine levels.
• The p38 pathway is a target of QKI in MEC2 cells.
• Lower QKI levels are observed in B-CLL patients and correlate with leukemia progression in a mouse model.

Conclusions:

• QKI is a key regulator of LPS signaling and inflammation.
• QKI plays a significant role in suppressing leukemogenesis, particularly in contexts involving miR-155.
• These findings highlight QKI's involvement in the pathophysiology of inflammation and miR-155-associated oncogenesis.